TY - JOUR
T1 - Telomerase-specific virotherapy in an animal model of human head and neck cancer
AU - Nakajima, Oumi
AU - Matsunaga, Atsuko
AU - Ichimaru, Daiju
AU - Urata, Yasuo
AU - Fujiwara, Toshiyoshi
AU - Kawakami, Koji
N1 - Copyright:
Copyright 2009 Elsevier B.V., All rights reserved.
PY - 2009/1/1
Y1 - 2009/1/1
N2 - Telomerase-specific replication-competent adenovirus, Telomelysin (OBP-301), has a human telomerase reverse transcriptase promoter that regulates viral replication and efficiently kills human cancer cells. The objectives of this study are to examine the effects of OBP-301 in squamous cell carcinoma of the head and neck cells in vitro and in xenografted animals in vivo. OBP-301 was found to be cytotoxic to the YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, HN12, and KCCOR891 cell lines in vitro. However, the level of cytotoxicity is not correlated with the expression levels of adenoviral receptors, which may be required for adenoviral infection in squamous cell carcinoma of the head and neck cells. OBP-301 shows remarkable antitumor activity against established s.c. KCCT873 tumors in immunodeficient animals in a dose-dependent manner. In addition, no significant toxicity was observed in animals receiving treatment. These results suggest that OBP-301 is a novel therapeutic agent with promise for the treatment of human head and neck cancers.
AB - Telomerase-specific replication-competent adenovirus, Telomelysin (OBP-301), has a human telomerase reverse transcriptase promoter that regulates viral replication and efficiently kills human cancer cells. The objectives of this study are to examine the effects of OBP-301 in squamous cell carcinoma of the head and neck cells in vitro and in xenografted animals in vivo. OBP-301 was found to be cytotoxic to the YCUT892, KCCT873, KCCT891, KCCL871, YCUM862, HN12, and KCCOR891 cell lines in vitro. However, the level of cytotoxicity is not correlated with the expression levels of adenoviral receptors, which may be required for adenoviral infection in squamous cell carcinoma of the head and neck cells. OBP-301 shows remarkable antitumor activity against established s.c. KCCT873 tumors in immunodeficient animals in a dose-dependent manner. In addition, no significant toxicity was observed in animals receiving treatment. These results suggest that OBP-301 is a novel therapeutic agent with promise for the treatment of human head and neck cancers.
UR - http://www.scopus.com/inward/record.url?scp=58149488625&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58149488625&partnerID=8YFLogxK
U2 - 10.1158/1535-7163.MCT-08-0620
DO - 10.1158/1535-7163.MCT-08-0620
M3 - Article
C2 - 19139126
AN - SCOPUS:58149488625
VL - 8
SP - 171
EP - 177
JO - Molecular Cancer Therapeutics
JF - Molecular Cancer Therapeutics
SN - 1535-7163
IS - 1
ER -
